882 results about "Growth inhibition" patented technology

The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.

An antimicrobial composition that contains an antimicrobial agent and a sugar alcohol is provided. The sugar alcohol is more generally more biocompatible and biodegradable than the antimicrobial agent. In addition, without intending to be limited by theory, it is believed that sugar alcohols increase the attraction of the antimicrobial agent to microorganisms (e.g., the cytoplasmic membrane of bacteria). Because a greater percentage of the antimicrobial agent molecules are brought into contact with the microorganisms, the efficiency of growth inhibition is increased. Thus, the antimicrobial composition provides good efficacy without the need for high levels of an antimicrobial agent.

The invention features methods for producing isoprene from cultured cells having increased expression levels and/or activity levels of a mevalonate kinase polypeptide and an isoprene synthase polypeptide. The invention also provides methods for producing isoprene from cultured cells having reduced accumulation of intermediates (such as mevalonate, isopentenyl diphosphate, 3,3-dimethylallyl diphosphate, geranyl diphosphate, or farnesyl diphosphate) in the biosynthesis of isoprene or isoprenoids that may otherwise cause undesirable amounts of growth inhibition, toxicity, or cell death. The resulting isoprene compositions may have increased yields and/or purity of isoprene.

The invention relates to the preparation of a functional area of a sea purse blood vessel growth inhibition factor 1 and the use of the functional area of the sea purse blood vessel growth inhibition factor 1 in medicaments for preventing and curing tumors. In the invention, a gene engineering technique is used to realize the cloning, expression and recombination of the sea purse blood vessel growth inhibition factor 1; the recombinant functional fragment of the sea purse blood vessel growth inhibition factor 1 has the bioactivities for resisting the growth of blood vessels, tumor growth, tumor transplantation, acute toxicity tests and stability tests; and the functional area of the sea purse blood vessel growth inhibition factor 1 can be mixed with or dissolved in pharmaceutically acceptable carriers to prepare the medicaments for curing various tumors. The functional area of the sea purse blood vessel growth inhibition factor 1 has high action specificity, has the characteristics of easy expression, low degradation rate and the like of gene engineering medicaments and has the effects of inhibiting blood vessel growth, tumor growth and tumor transplantation; the provided gene engineering technique can realize the industrial production of the functional area of the sea purse blood vessel growth inhibition factor 1; and the functional area of the sea purse blood vessel growth inhibition factor 1 prepared by the gene engineering technique can be used in the preparation of medicaments for inhibiting blood vessel growth and preventing and curing tumors.

The invention searches the novel micromolecule inhibitor pyrazolo (1, 5-a) miazines compounds of cyclin-dependent kinase CDK9 (cyclin-dependent kinase) through the virtual screening of a computer, biometrically measures activity thereof, and validates interaction mechanism. The invention specifically comprises the following steps: the three-dimensional crystal conformation of the cyclin-dependent kinase family member CDK9 is obtained in a way of homology modeling; and micromolecule three-dimensional database is screened with DOCK (molecular docking). The invention uses a MTT tumor cell growth inhibition test to biometrically measures the activity of the selected compounds, researches the selected compounds pyrazolo (1, 5-a) miazines with high activety in a way of molecular mechanism, validates the inhibiting effect of the compounds to the activity of CDK9 kinase, and clarifies the interaction mechanism of the compounds for inhibiting the external activity and the molecule of various malignancies such as lung cancer, osteosarcoma, oophoroma, cervical carcinoma, breast cancer, etc.

The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.

The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab' domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.

The invention relates to a bacillus subtilis str.TR21 (hereinafter referred to as 'TR21') strain having broad-spectrum antagonism to plant pathogenic fungi, in particular to the bacillus subtilis TR21 strain and a growth inhibition function thereof on the plant pathogenic fungi. The bacillus subtilis TR21 strain provided by the invention is preserved in China Center for Type Culture Collection (CCTCC) in January 20, 2010 with a preservation number of CCTCC No: M2010019, wherein the China Center for Type Culture Collection is located in Wuhan University, Lojia Mountain, Wuchang, Hubei, China. The strain provided by the invention is proved by obtained gene segments 16S rDNA, gyrA and gyrB and BLAST search and comparison on NCBI to be a novel bacillus subtilis strain having relatively higher flat antagonistic activity to a plurality of plant pathogenic fungi, particularly having high antagonism to various soil borne vascular diseases, such as fusarium oxysporum, rhizoctonia solani, alternaria and the like, and having good prevention and control effects shown in fields.

The invention discloses dsRNA (double-stranded ribonucleic acid) and application to aphid growth inhibition. The dsRNA provided by the invention is dsRNA as expressed by 1) or 2) as follows: 1) dsRNA consisting of ribonucleic acid as shown by a sequence 4 in a sequence table and ribonucleic acid as shown by a reverse complementary sequence of the sequence 4; and 2) dsRNA consisting of ribonucleicacid as shown by a sequence 5 in the sequence table and ribonucleic acid as shown by a reverse complementary sequence of the sequence 5. According to experiments, the obtained dsRNA of a conserved sequence of cytochrome P450cDNA (complementary deoxyribonucleic acid) of English grain aphids and green peach aphids can inhibit growth and development of the English grain aphids and the green peach aphids and can cause a lethal effect by adopting a method of feeding the dsRNA in vitro and using an RNAi (ribonucleic acid interfere) technology to silence the in-vivo cytochrome p450 of the English grain aphids and the green peach aphids.

The present invention relates to a therapeutic method using RNAi directed at BRAF, of which the point mutation, especially V599E, occurs frequently in melanomas. RNAi specific for the mutated BRAF will provide a specific therapeutic intervention for cancers such as malignant melanoma. Several target sequences for RNAi were selected in the protein coding region of the BRAF mRNA. The short hairpin RNA expression cassette was constructed on the lentiviral vector. One recombinant viral vector for the mutated BRAF V599E and two other vectors sites for wild type BRAF were constructed to infect various malignant melanoma cell lines, and the effects on the growth inhibition and the signaling of MAPK pathway were examined. The inhibitory effect on the invasion ability of malignant melanoma cell line and in vivo growth of a malignant melanoma cell line were examined.

The invention discloses 14 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters shown in the general formula I. In the general formula I, AA represents L-Ser residue, L-Glu (OBzl) residue, L-Phe residue, L-Val residue, L-Arg residue, L-Tyr residue, L-Ala residue, L-Trp residue, L-Asn residue, L-Met residue, L-Ile residue, Gly residue, L-Asp (OBzl) residue or L-Leu residue. The invention discloses a preparation method of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, discloses HT-29, K562, A549 and HL60 tumor cell growth inhibition effects of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, further discloses S180-loading mice tumor growth inhibition effects of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, and also discloses use of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters as antitumor drugs.

A method for determining whether a microorganism produces an AmpC β-lactamase is disclosed in which a culture of a microorganism suspected of producing a β-lactamase that inactivates a β-lactam-containing antibiotic is admixed with an effective amount of each of i) a β-lactam-containing antibiotic, ii) a β-lactamase inhibitor to which AmpC β-lactamase is resistant, and iii) a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing amount to form an assay culture. That assay culture in maintained under appropriate culture conditions and for a time period sufficient to determine the interaction of the microorganism with the AmpC β-lactamase resistant inhibitor and antibacterial compound, and thereby determine the presence of an AmpC β-lactamase, wherein a positive test indicates the presence of an AmpC β-lactamase.

An individual's susceptibility to cancer is assessed based on the individual's cellular response to mutagenic agents such as radiation. The level of a growth-suppressing marker is measured before and after the individual's cells are exposed to the mutagenic agent. The individual's susceptibility to cancer as a result of the mutagenic agent is correlated with the degree to which the growth-suppressing marker is induced by exposure to the agent. A method is also disclosed for assessing cancer prophylaxis effects of compounds, such as vitamins or food extracts, in individuals. Cells from an individual are incubated with at least one compound in vitro, or the compound is directly administered to the individual, after which some of the incubated cells, as well as non-incubated cells, are exposed to a mutagenic agent such as ionizing radiation. The level of the growth-suppressing marker in the cells incubated with the compound and exposed to the mutagenic agent is then compared with the level in the non-incubated cells exposed to the agent. The cancer prophylaxis effects of the compound are correlated with a higher level of the marker in the incubated cells.

The invention discloses a green, long-lasting antibacterial, mildew-resistant and insecticidal water-based micro-emulsifier. The green, long-lasting antibacterial, mildew-resistant and insecticidal water-based micro-emulsifier is characterized in that an insect growth regulator (IGR) is utilized as a main component; auxiliary components comprise multi-component plant essential oil and/or low-toxicity high-efficiency pesticides, bactericides, synergists, penetrants, water-soluble solvents, surfactants and a stabilizing agent; and the green, long-lasting antibacterial, mildew-resistant and insecticidal water-based micro-emulsifier satisfies prevention and control requirements of different places. The green, long-lasting antibacterial, mildew-resistant and insecticidal water-based micro-emulsifier has a wide insecticidal spectrum, high efficiency, an ovicidal function, an insect growth inhibition function and a long persistent period, avoids drug resistance, has bacteriostasis and mildew-resistance effects, a low residue amount and low toxicity to mammals, avoids pollution caused by pesticide application imbalance, and is conducive to the ecological environment. The green, long-lasting antibacterial, mildew-resistant and insecticidal water-based micro-emulsifier can be sprayed on an object, does not produce imprints, does not pollute stored objects, is suitable for bacteriostasis, mildew-resistance and pest killing of stored objects and plants, especially, is suitable for killing and control of insects, mites, mould and harmful bacteria on stored objects such as stored grains, tobacco, medicinal materials, leather, clothes, books, archives and historical relics, and can reduce the loss caused by insect damage and mildewing of stored objects and grains.